Profile Response Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com


Molecular Profile ERBB3 positive
Therapy Patritumab deruxtecan
Indication/Tumor Type Her2-receptor negative breast cancer
Response Type predicted - sensitive

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
ERBB3 positive Her2-receptor negative breast cancer predicted - sensitive Patritumab deruxtecan Clinical Study Actionable In a clinical study, Patritumab deruxtecan (U3-1402) treatment demonstrated efficacy in patients with ERBB3 (HER3)-positive, ERBB2 (HER2)-negative breast cancer, resulting in increased immune infiltration as measured by a median increase of 3.5 in the CelTIL score, and an overall response rate of 45.2% (28/62, 14 complete and 14 partial responses) (PMID: 37211044; NCT04610528). 37211044
ERBB3 positive Her2-receptor negative breast cancer predicted - sensitive Patritumab deruxtecan Phase II Actionable In a Phase II trial, Patritumab deruxtecan (U3-1402) treatment resulted in an objective response rate (ORR) of 35%, clinical benefit rate (CBR) of 48%, median duration of response of 10 mo, and 6-mo progression-free survival (PFS) rate of 60% in ERBB3 (HER3)-positive, ERBB2 (HER2)-negative metastatic breast cancer patients, with an ORR of 46 vs 33%, CBR of 54 vs 50%, and PFS rate of 70 vs 50% in those with 25-75% vs >/=75% ERBB3 (HER3) expression (J Clin Oncol 41, 2023 (suppl 16; abstr 1004); NCT04699630). detail...
ERBB3 positive Her2-receptor negative breast cancer predicted - sensitive Patritumab deruxtecan Phase Ib/II Actionable In a Phase I/II trial (U31402-A-J101), Patritumab deruxtecan (U3-1402) therapy demonstrated safety and efficacy in previously treated metastatic hormone receptor-positive, ERBB2 (HER2)-negative breast cancer patients expressing ERBB3 (HER3) (n=113), with an objective response rate of 30.1%, disease control rate of 80.5%, with partial response in 30.1% and stable disease in 50.4% of patients, median progression-free survival of 7.4 mo, and median overall survival of 14.6 mo (PMID: 37801674; NCT02980341). 37801674
PubMed Id Reference Title Details
(37211044) Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative study. Full reference...
A phase 2 study of HER3-DXd in patients (pts) with metastatic breast cancer (MBC). Full reference...
(37801674) Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3-Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3-Expressing Metastatic Breast Cancer: A Multicenter, Phase I/II Trial. Full reference...